Loss of Sarm1 does not suppress motor neuron degeneration in the SOD1<sup>G93A</sup> mouse model of amyotrophic lateral sclerosis

Owen M. Peters<sup>1,2,†,1,*</sup>, Elizabeth A. Lewis<sup>1,†</sup>, Jeannette M. Osterloh<sup>1</sup>, Alexandra Weiss<sup>2</sup>, Johnny S. Salameh<sup>2</sup>, Jake Metterville<sup>2</sup>, Robert H. Brown<sup>2,§</sup> and Marc R. Freeman<sup>1,‡,§</sup>

<sup>1</sup>Department of Neurobiology, University of Massachusetts Medical School, Worcester, MA, USA and <br>2Department of Neurology, University of Massachusetts Medical School, Worcester, MA, USA

*To whom correspondence should be addressed at: School of Biosciences, Haydn Ellis Building, Cardiff University, Cardiff, Wales CF24 4HQ, UK. <br>Email: PetersOM@Cardiff.ac.uk

Abstract

Axon degeneration occurs in all neurodegenerative diseases, but the molecular pathways regulating axon destruction during neurodegeneration are poorly understood. Sterile Alpha and TIR Motif Containing 1 (Sarm1) is an essential component of the prodegenerative pathway driving axon degeneration after axotomy and represents an appealing target for therapeutic intervention in neurological conditions involving axon loss. Amyotrophic lateral sclerosis (ALS) is characterized by rapid, progressive motor neuron degeneration and muscle atrophy, causing paralysis and death. Patient tissue and animal models of ALS show destruction of upper and lower motor neuron cell bodies and loss of their associated axons. Here, we investigate whether loss of Sarm1 can mitigate motor neuron degeneration in the SOD1<sup>G93A</sup> mouse model of ALS. We found no change in survival, behavioral, electrophysiological or histopathological outcomes in SOD1<sup>G93A</sup> mice null for Sarm1. Blocking Sarm1-mediated axon destruction alone is therefore not sufficient to suppress SOD1<sup>G93A</sup>-induced neurodegeneration. Our data suggest the molecular pathways driving axon loss in ALS may be Sarm1-independent or involve genetic pathways that act in a redundant fashion with Sarm1.

Introduction

Axon degeneration is a hallmark of neurodegenerative disease (1), but we lack a detailed understanding of the signaling pathways that promote this destructive process in any major disorder. Significant progress has however been made in the characterization of molecules that regulate axon destruction after axotomy, termed Wallerian degeneration (2). Initial molecular insights into Wallerian degeneration came from the...
spontaneous mouse mutant Wallerian degeneration slow (Wld\textsuperscript{s}) (3). Remarkably, while severed axons of wild-type mice typically undergo destruction and clearance within days, Wld\textsuperscript{s} mutant axons remain intact for weeks after lesion. This neuroprotective effect of Wld\textsuperscript{s} mapped to a genome rearrangement producing a neomorphic fusion protein (4), with the key protective activity determined to be that of Nicotinamide adenine dinucleotide (NAD\textsuperscript{+}) biosynthetic enzyme nicotinamide mononucleotide adenyltransferase 1 (Nmnat1) (5). The Wld\textsuperscript{s} mutant radically changed our views on axon biology—demonstrating that axon destruction could be regulated and that under some conditions axons could survive for long periods without a cell body.

Is there an endogenous pathway that actively drives axon auto-destruction? An unbiased forward-genetic screen in Drosophila for mutants that phenocopied Wld\textsuperscript{s} led to the discovery of the Sterile Alpha and TIR Motif Containing 1 (dSarm/Sarm1), a founding member of the axon death signaling pathway engaged after axotomy (6). In adult mice, dSarm null mutant backgrounds, distal severed axons survived for weeks post-axotomy, an effect that was found to be conserved after sciatic nerve lesion in mice (6,7). Moreover, as the Sarm1 protein is highly conserved between humans and rodents (Human accession number: Q6SZW1-1, Mouse accession number Q6PD63-1; 94% identity, 99% coverage), functional conservation is likely. At least two additional genes have subsequently been identified as similarly potent regulators of axon degeneration: the E3 ubiquitin ligase Phr1/Highwire (8–10) and the bric-a-brac, tramtrack, broad complex (BTR/BTB and C-terminal Kelch (BACK) domain containing gene Axundead (11).

Given that each of these molecules are essential for efficient axon degeneration after axotomy, they represent exciting new potential targets for therapeutic blockade of axon loss in disease. The mitigating activity of Wld\textsuperscript{s} has previously been assessed in models of toxic-induced neuropathies (12,13), gracile axonal dystrophy (14), glaucoma (15,16), Parkinson’s disease (17,18) and motor neuron diseases including amyotrophic lateral sclerosis (ALS) (19–21) and met with some success, suggesting that treating the axon is a viable approach. The discovery of Sarm1 and other axon death signaling molecules warrants a reassessment of the role of axon degeneration pathways in neurodegenerative diseases. Indeed, a recent study has demonstrated that the deletion of Sarm1 is in fact significantly more protective than Wld\textsuperscript{s} expression in an Nmnat2 deletion model of nerve degeneration (22).

ALS exists in idiopathic and less common familial forms and is characterized by progressive paralysis, a consequence of profound destruction of motor neurons and their axons (23). Notably, Single nucleotide polymorphisms associated with Sarm1 have been detected in genome-wide association study of sporadic ALS patients, suggesting the gene may even play a direct role in ALS pathogenesis (24). In this study we tested whether elimination of Sarm1 was sufficient to block axon destruction by the human SOD1\textsuperscript{G93A} mutant molecule in the transgenic mouse model of ALS. We found that loss of Sarm1 was sufficient to block Wallerian degeneration in 1-year-old control mice, and at early stages in transgenic mice expressing mutant SOD1. However, elimination of Sarm1 was not sufficient to mitigate behavioral, morphological or electrophysiological deficits observed in motor neurons in the ALS mouse. Our findings indicate the molecular pathways driving axon loss in the SOD1\textsuperscript{G93A} model may be Sarm1-independent or that in the context of disease Sarm1 acts in a redundant fashion with other pro-degenerative signaling pathways.

Results

Degeneration of severed axons in aged mice is ameliorated by loss of Sarm1

The paralytic symptoms of ALS result from the progressive degeneration of upper and lower motor neurons and their axons, with typical disease onset in adulthood and risk increasing with age. We have previously demonstrated that when severed in vivo, peripheral nerve axons of young Sarm1 null mice are more robustly protected against Wallerian degeneration (6). For Sarm1 to be a viable target for treatment of ALS or other late-onset neurodegenerative diseases this mechanism of programmed axon destruction must be maintained in aged neurons. To test this, we lesioned the sciatic nerves of 1-year-old Sarm1\textsuperscript{KO} mice and inspected the morphology of myelinated axons in the distal, severed nerve portion 14 days post-lesion (Fig. 1A). Consistent with young animals the nerves of aged wild-type control mice were in a highly degenerate state, with normal myelinated axons absent. In Sarm1\textsuperscript{KO} mice, however, a substantial proportion of axons retained normal morphology, included being enclosed by an intact myelin sheath. Protection at this mature adult stage demonstrates that, rather than being a mechanism retained from development in young adult neurons, Sarm1-mediated axon destruction is an intrinsic characteristic of post-developmental neurons that may contribute to neurodegeneration and injury.

Mutant SOD1\textsuperscript{G93A} does not impede protection against Wallerian degeneration in Sarm1 null nerves

SOD1\textsuperscript{G93A} transgenic mice express high levels of mutant SOD1 protein throughout their nervous system (25). It was important to confirm that excessive levels of this protein did not interfere with normal Sarm1-mediated Wallerian degeneration. Sciatic nerve axotomy experiments were conducted in young SOD1\textsuperscript{G93A} transgenic mice that were Sarm1 heterozygous (Sarm1\textsuperscript{HET}), where axotomy phenotype is as wild type or null for Sarm1 (Fig. 1B). At 14 days post-lesion myelinated axons of Sarm1\textsuperscript{HET} mice expressing SOD1\textsuperscript{G93A} underwent axon degeneration comparable to that observed in control Sarm1\textsuperscript{WT} and aged Sarm1\textsuperscript{KO} (Fig. 1A) animals. Mutant SOD1 transgenic axons in Sarm1\textsuperscript{KO} mice were comparably protected from Wallerian degeneration to those of Sarm1\textsuperscript{KO} control mice, confirming that the human SOD1\textsuperscript{G93A} transgene does not impede protection of severed axons.

Blocking Sarm1-mediated axon destruction does not alter the acquisition of motor defects in the SOD1\textsuperscript{G93A} transgenic mouse

Having confirmed Sarm1-mediated Wallerian degeneration occurs normally in the SOD1\textsuperscript{G93A} transgenic mouse, we next tested if this mechanism contributes to the chronic neurodegenerative and subsequent paralytic phenotype developed by these animals (Fig. S1). We generated a colony of SOD1\textsuperscript{G93A} transgenic mice either heterozygous for Sarm1, where Wallerian degeneration occurs normally, or homozygous null for Sarm1 where distal severed axons are preserved (Fig. 1B). Mice were blindly scored daily for onset of tremor at early stages of disease and onset of paralysis of the hind limbs at later stages (Fig. 2A,B). There was no significant difference in the presentation of either of these symptoms between Sarm1 heterozygous or null SOD1\textsuperscript{G93A} transgenic mice (Sarm1\textsuperscript{HET} SOD1\textsuperscript{G93A}, n = 37;
SARM1-mediated axon destruction can be suppressed in aged mice and is not altered by transgenic expression of mutant SOD1. (A) Representative micrographs showing toluidine blue-stained intact or axotomized sciatic nerves of 1-year-old wild-type SARM1KO mice. Morphologically intact axons were widespread in the distal sciatic nerve 14-day post-lesion in SARM1KO mice. (B) Representative images of intact or axotomized sciatic nerve of 5-week-old control and SOD1G93A transgenic mice 14 days post-axotomy, showing preservation of axons in SARM1KO mice. Scale bar = 20 μm.

SARM1KO SOD1G93A, n = 44. Tremor onset: SARM1Het SOD1G93A, 78.0; SARM1KO SOD1G93A, 79.5. Log-Rank (Mantel–Cox test): χ² = 0.8999, df = 1, P-value = 0.3428. Hind limb paralysis onset: SARM1Het SOD1G93A, 165.0; SARM1KO SOD1G93A, 166.0. Log-Rank (Mantel–Cox test): χ² = 0.1047, df = 1, P-value = 0.7462). Furthermore, no difference was detected in lifespan between SOD1G93A transgenic mice heterozygous or null for SARM1 (Fig. 2C) (SARM1Het SOD1G93A, n = 37; SARM1KO SOD1G93A, n = 44; SARM1Het SOD1G93A, 167.0; SARM1KO SOD1G93A, 167.0. Log-Rank (Mantel–Cox test): χ² = 0.005961, df = 1, P-value = 0.9385). We next assayed for potential rescue of sensorimotor function in the SARM1KO background more quantitatively by using rotarod (Fig. 2D) and grip strength testing (Fig. S2). Though SOD1G93A expression resulted in progressive and significant decline in motor performance post-hoc tests did not detect any significant changes in sensorimotor defects associated with SOD1G93A in the SARM1 null background compared to sibling heterozygous controls in either rotarod (SOD1G93A groups, n = 20; control groups, n = 15; FInteraction (34 864) = 11.75, P-value < 0.0001; FTreatment (17 864) = 35.34, P-value < 0.0001; FGenotype (2864) = 559.2, P-value < 0.0001; Bonferroni post-hoc analysis detected no significant differences between SOD1G93A transgenic groups) or grip strength test (Fig. S2). These data indicate that elimination of SARM1 is not sufficient to delay the onset or progression of the chronic motor deficits in the SOD1G93A mice.

ALS-associated deficits in neuromuscular electrophysiological function are not protected by loss of SARM1

Although removed from neuronal circuits through loss of their cell body and dendrites, severed axons protected from Wallerian degeneration are able to maintain electrophysiological function and evoke action potentials in response to artificial stimulation (4,11). It was thus feasible that despite not ameliorating the overall ALS-like phenotypes of SOD1G93A mouse, SARM1 null motor neurons may preserve their total number and size of their motor units and maintain their ability to conduct action potentials relative to SOD1G93A mice expressing SARM1.
Figure 2. Sarm1 does not contribute to onset, survival or sensorimotor performance deficits in SOD1G93A mice. Percentage of transgenic colony free of (A) hind limb tremor and (B) hind limb paralysis. (C) Kaplan–Meier plot showing survival of transgenic cohorts (A–C: Sarm1Het SOD1G93A, n = 37; Sarm1KO SOD1G93A, n = 44; Sarm1Het control, n = 31; Sarm1KO control, n = 27; Sarm1Het SOD1G93A vs Sarm1KO SOD1G93A; Log-Rank test, P-value > 0.05). (D) Fall latency of male transgenic mice on 4–40 rpm accelerating rotarod task for assessment of sensorimotor function (SOD1G93A groups, n = 20; control groups, n = 15; two-way ANOVA with Bonferroni post-hoc test).

To explore this possibility we used motor unit number estimation (MUNE) (26) to quantify several features of electrophysiological functional decline in the gastrocnemius muscle of our experimental cohorts (Fig. 3, S3). MUNE gives an estimation of the number of intact motor units present in a stimulated muscle, providing a robust read-out of neuromuscular electrophysiological decline in both ALS patients and rodent models (27,28). Assessment of adult control mice wild-type, heterozygous or homozygous null for Sarm1 detected no significant difference in the MUNE score. Therefore, loss of Sarm1 does not affect normal neuromuscular electrophysiological function as measured by MUNE (Fig. 3A). However, in p120–130 mice expressing the SOD1G93A transgene we found a significant reduction in MUNE score (n = 4–14; two-way analysis of variance (ANOVA): F_Sarm1Genotype (2,37) = 1.692, P-value = 0.1981; F_SOD1Genotype (1,37) = 301.4, P-value < 0.0001; Bonferroni post-hoc test, ***P-value < 0.0001). Loss of Sarm1 did not have a significant effect at this point nor at the early symptomatic p80–90 stage (Fig. S3). As MUNE score declines in ALS, a compensatory increase in motor unit size is seen with in both patients (28) and rodent models (27). Expression of SOD1G93A indeed resulted in an increased motor unit size in controls, which was also present in all Sarm1 genotypes at p120–130 when compared to their littermate controls not expressing the SOD1G93A transgene, although this trend was not statistically significant in the Sarm1KO cohort (Fig. S3B). Post-hoc analysis between SOD1G93A transgenic mice of differing Sarm1 genotypes revealed no significant difference between motor unit size in Sarm1 genotypes at p120–130 (n = 4–14; two-way ANOVA: F_Sarm1Genotype (2,37) = 1.148, P-value = 0.3283; F_SOD1Genotype (1,37) = 43.48, P-value < 0.0001; Bonferroni post-hoc test, **P-value < 0.01) or the earlier p80–90 time point (Fig. S3C). Changes in motor unit size are a result of plasticity at the neuromuscular junction (NMJ) synapse. These data reveal that loss of Sarm1 does not play a biologically significant role in protecting motor unit size from increases in the context of the SOD1G93A model, arguing that loss of Sarm1 does not affect major aspects of synaptic plasticity.

Finally, we assessed compound motor action potential (CMAP), a measure of total activity from synchronized action potentials reaching the muscle following simultaneous stimulation of multiple axons within a bundle. As with MUNE, total CMAP within the gastrocnemius was significantly reduced in mice expressing SOD1G93A. In control mice, the total CMAP was not altered in Sarm1KO animals compared to Sarm1Het or Sarm1WT, indicating loss of Sarm1 does not alter CMAP properties; however, the absence of Sarm1 did not ameliorate the deficits in CMAP observed in the presence of SOD1G93A (Fig. 3C; n = 4–14; two-way ANOVA: F_Sarm1Genotype (2,37) = 3.152, P-value = 0.0545; F_SOD1Genotype (1,37) = 260.5, P-value < 0.0001; Bonferroni post-hoc test, ***P-value < 0.0001). Together, these data reveal that overall neuromuscular properties are relatively normal in Sarm1KO animals, and that blockade of Sarm1 signaling alone is not sufficient to alter the decline in electrophysiological function of motor neurons in SOD1G93A mice.

Loss of Sarm1 does not preserve motor neuron axons or terminals in SOD1G93A transgenic mice

Neurodegeneration occurs throughout motor neurons of SOD1G93A transgenic mice, with the cell body, axons and NMJs all being lost during the progression of pathology (29). Interestingly, these neurodegenerative mechanisms appear to be somewhat compartmentalized: suppression of apoptosis in SOD1 transgenic mice preserves spinal cord motor neuron cell bodies but does not rescue motor axons nor disease progression (30). Although we found that loss of Sarm1 failed to ameliorate any of the behavioral and physiological phenotypes of SOD1G93A...
transgenic mice, it was conceivable that motor axons might remain morphologically intact with pathology being driven by degeneration of cell bodies or dendrites rendering the cells inactive. To determine whether axons were preserved we first quantified the number of myelinated motor axons within the L5 ventral nerve root mutant morphology present within the L5 ventral nerve root mutant SOD1G93A transgenic cohorts at early, mid and end stages of pathology. When compared to transgenic mice carrying Sarm1, we found that no significant differences in number of healthy axons were seen in Sarm1 null mice at any stage in pathology (Fig. 4A–C: p90 SOD1G93A Sarm1WT, n = 4; SOD1G93A Sarm1Het, n = 4; SOD1G93A Sarm1KO, n = 3. One-way ANOVA: F_{Sarm1Genotype} (2,8) = 1.133, P-value = 0.368; p120–130 SOD1G93A Sarm1KO, n = 4; SOD1G93A Sarm1Het, n = 11; SOD1G93A Sarm1KO, n = 7.

One-way ANOVA: F_{Sarm1Genotype} (2,19) = 2.272, P-value = 0.1304; end-stage SOD1G93A Sarm1 Het, n = 3; SOD1G93A Sarm1 KO, n = 6. Unpaired two-tailed t test: t = 1.974, df = 7, P-value = 0.089).

Figure 3. Deficits in neuromuscular electrophysiological function associated with SOD1G93A expression are not ameliorated in mice lacking Sarm1. Neuromuscular electrophysiological function was tested in SOD1G93A and control mice of Sarm1WT (black), Sarm1Het (blue) or Sarm1KO (red) genotype. Assessing the gastrocnemius muscle of p120–130 mice for (A) MUNE, (B) motor unit size and (C) CMAP failed to show any significant difference in phenotype between SOD1G93A transgenic groups (mean ± SEM, n = 4–14; two-way ANOVA with Bonferroni post-hoc test; ns = non-significant; *P-value < 0.05; **P-value < 0.01; ***P-value < 0.001).

Discussion

The promotion of regulated axon destruction by Sarm1 presents an appealing target for the treatment of neurodegenerative diseases and injury where pronounced axon degeneration occurs. In the present study we found that genetic suppression of Wallerian-like axon destruction by deletion of Sarm1 neither attenuates axon degeneration nor alters hallmark features of disease progression in the SOD1G93A transgenic mouse model of ALS. Our findings are in line with previous studies of the role of Wallerian-like degeneration in models of motor neuron diseases. Expression of the potent suppressor of Wallerian degeneration Wld^d in models of motor neuron degeneration previously yielded varied results, with only modest protection having been reported in SOD1G93A transgenic mice (20). Similarly, the degenerative phenotypes in SOD1G93A or SOD1G85A transgenic mouse models were not changed by the presence of Wld^d (21). However, in the pmn mouse model of progressive motor neuronopathy, which entails axon degeneration followed by motor neuron death, Wld^d significantly suppressed axon loss, rescued motor neuron death and extended animal lifespan (19). These observations validate the notion that treating the axon in some contexts can save neurons, but our data suggest that blocking axon degeneration alone with Sarm1 is not sufficient.
Figure 4. Progressive loss of myelinated motor axons is not ameliorated by loss of Sarm1. Total number of myelinated axons in the L5 ventral nerve root of SOD1<sup>G93A</sup> transgenic mice wild type, heterozygous-null or homozygous-null for Sarm1 at (A) p80–90, (B) p120–130 and (C) end stage (n = 3–11, mean ± SEM; A and B, one-way ANOVA; C, Student t test). Frequency distribution of axon diameters at (A′) p90, (B′) p120 and (C′) endpoint expressed as percentage of total axons measured (mean ± SEM, two-way ANOVA with Bonferroni post-hoc test, *P-value < 0.05, **P-value < 0.01). (D) Representative images of L5 ventral nerve root myelinated axons at p120 in SOD1<sup>G93A</sup> mice wild-type, heterozygous-null or homozygous-null for Sarm1 with comparison images from littermate controls not expressing SOD1<sup>G93A</sup> (scale bar = 20 μm).

to ameliorate SOD<sup>G93A</sup> mutant phenotypes. Perhaps the severity and rapid time scale of pathology in SOD1 transgenic rodent models pose a limitation in these studies. Although this model recapitulates the cardinal pathologies of ALS, the potency of high-level overexpression of SOD<sup>G93A</sup> might potentially mask any modifying effects of Sarm1 on disease progression.

The contribution of Wallerian-like axon degeneration in ALS-associated phenotypes has also been tested in invertebrate models. Loss of Tir-1, the Caenorhabditis elegans homolog of Sarm1, delays paralysis induced by expression of mutant of FUS RNA Binding Protein or TAR DNA-Binding Protein 43 (TDP-43) in worms (31). The authors suggest expression of the ALS mutant genes leads to secretion of currently unknown molecules from neurons, activating Tir-1 and the downstream MAP-kinase cascade triggering both an innate immune response and neuron degeneration, though an effect upon neuronal morphology was not reported. In contrast, neither the expression of Wld<sup>+</sup> nor loss of dSarm or Phrl/Highwire was found to delay morphologically defined degeneration of NMJ in Drosophila expressing mutant TDP-43 in motor neurons (32). Taken together these in vivo studies in rodent and invertebrate models of ALS argue the molecular pathways promoting Wallerian degeneration, may not be the primary drivers of axon loss or, at a minimum, are functionally redundant with other prodegenerative signaling pathways.

We have found Sarm1 to robustly drive Wallerian axon destruction at both juvenile (Fig. 1B,(6)) and mature adult stages (Fig. 1A), demonstrating that the genes role in this degenerative process is neither restricted to development nor substantially impeded by age. Why, however, inhibition of Sarm1 mediated axon degeneration has such a profound effect on Wallerian degeneration even in neurons at advanced ages but fails to ameliorate ALS-associated neurodegeneration is unclear. Our study demonstrates that in Sarm1 null animals expressing mutant SOD1, Wallerian degeneration of the distal injured axon is impeded (Fig. 1B) but not ALS-associated axonal degeneration (Fig. 4D). Whether any of these models meaningfully recapitulate the molecular mechanisms driving axon loss in patients remains unclear; but if so, our findings suggest the underlying mechanisms may be molecularly distinct.

The role of mitochondria in different forms of neurodegeneration may also be a factor, with evidence suggesting
mitochondrial biology contributes to the protective activity of Sarm1 and WldS. Both proteins localize to mitochondria (33-35), with Sarm1 robustly protecting cultured neurons from the downstream reactive oxygen stress caused by mitochondria uncoupling (36). Though there is some evidence of mitochondria abnormalities in SOD1 transgenic mice (30,37), it however

Figure 5. Sarm1 does not contribute to NMJ denervation in SOD1G93A transgenic mice. (A) Representative images of immunofluorescent staining of NMJs in the gastrocnemius muscle at p120–130. (Green = synaptophysin and beta-III-tubulin co-stain, Red = alpha-bungarotoxin, scale bar = 50 μm) (B) Percentage of innervated NMJs in the gastrocnemius muscles of transgenic cohorts at p120–130 (mean ± SEM, n = 3–5, two-way ANOVA with Bonferroni post-hoc test, *P-value < 0.05, **P-value < 0.01, ***P-value < 0.001).
remains uncertain whether this is a driving mechanism behind neurodegeneration rather than a secondary response to poor health of the neuron. Interestingly, mitochondria damage in ALS may play a role in altered levels of NAD+. The protective activity of both WldS overexpression and Sarm1 deletion is likely dependent on maintaining neuronal levels of NAD+. Fragmentation of mitochondria seen in cultured motor neurons expressing mutant SOD1 can be rescued by expression of the NAD+-dependent sirtuin SIRT3 (38), suggesting that maintaining high levels of NAD+ may be beneficial to neuronal survival in ALS. However, investigating the neuronal contribution of NAD+ in vivo is complicated by its function in maintaining normal glial activity. Depleted levels of NAD+ in cultured astrocytes drive oxidative stress in the cells, subsequently contributing to their toxicity toward co-cultured neurons, an effect that can be rescued by increasing levels of astrocytic NAD+ (39). Further analysis of the role of NAD+ in neurons, an effect that can be rescued by increasing levels of astrocytic NAD+ (39). Further analysis of the role of NAD+ in ALS and other neurodegenerative disease is required to increase our understanding of how this molecule contributes to diverse forms of axon destruction.

Indeed, the process by which motor axons degenerate in ALS does not appear to be Wallerian-like; loss of distal motor axons occurs prior to onset of symptoms in SOD1 transgenic mouse models (40), progressing in a dying back pattern ultimately leading to death of motor neuron cell bodies late in disease (29). In contrast, Wallerian degeneration is characterized by explosive, widespread fragmentation of the axon following severing along its entire length. Interestingly, axonal injury has previously been found to result in exacerbated degeneration of motor neuron cell bodies in the spinal cords of SOD1G93A transgenic mice (43, Neuroscience), suggesting the proximal portion of damaged axons may contain a signaling cascade to enhance destruction of the cell body. Notably, Sarm1 was found to improve acute responses in a mouse model of traumatic brain injury, where crush and shear injuries to axons are more typical (41). We therefore speculate that multiple, potentially parallel mechanisms for axon destruction exist: an acute pathway in which Sarm1 (and an emerging cascade of downstream factors) drives the destruction of severed axons and a second distinct mechanism that occurs as axons undergoing chronic pathology in neurodegenerative disease. This latter pathway may involve Sarm1, but based on our data, we would predict in that case that Sarm1 acts in a redundant fashion with other pathways that are capable of executing axon degeneration even in the absence of Sarm1. Future examination of additional Wallerian degeneration molecules (e.g. Phr1 and Axundead) in these models should clarify this issue. Furthermore, it seems likely that selective protection of axons from degeneration without additionally impeding the destruction of other cellular compartments like the soma might be insufficient to entirely block neurodegeneration in ALS. Notably inhibition of cell body death through deletion of the pro-apoptotic gene Bax, though effective in rescuing cell body death, did not to delay the progression of motor behavior functional decline in SOD1 transgenic mice (30).

Further exploration of the Sarm1 signaling pathway in neurodegeneration is warranted given the ability of Sarm1<sup>1/2</sup> to attenuate axon loss and improve behavioral outcomes in models of Traumatic Brain Injury (TBI) (41) and peripheral neuropathy (44). The role of Sarm1 in promoting axon degeneration may indeed be context-dependent. That the nerve lesioning experiments in our study found Sarm1 to drive axon destruction in both young and aged axons suggests it may still be a viable target for both juvenile (i.e. spinal muscular atrophy) and age-associated neurodegenerative disease (i.e. Parkinson’s, Alzheimer’s, glaucoma). Until comprehensively tested in the variety of models of neuronal injury and neurodegeneration we will not know the full potential of Sarm1 and its associated axon-destruction cascade as a therapeutic target.

Materials and Methods

Animals/scoring

High expression hSOD1<sup>G93A</sup> (B6.Cg-Tg(SOD1<sup>G93A</sup>)1Gur/J) and Sarm1 knockout (B6.129X1-Sarm1<sup>tm1Aidi</sup>/J) mice were acquired from Jackson Labs and maintained on a C57Bl6/J backgrounds, in a 12-hr light/dark cycle with ad libitum access to food and water. Transgenic colonies were generated by breeding male mice heterozygous for both Sarm1 and SOD1<sup>G93A</sup> transgene with Sarm1 heterozygous or null females. Mice were scored daily by researchers blinded to genotype for onset of trembling or dragging/paralysis of one or more hind limbs. End-stage mice unable to right within 30 s were euthanized. To encourage feeding, animals approaching end stage had access to wet mash food and gel water packs on their cage floor. For histological experiments, littermate control mice not expressing the SOD1<sup>G93A</sup> transgene older than p200 were used for comparison to transgenic litters. Experiments were approved by the University of Massachusetts Medical School Institutional Animal Care and Use Committee.

Genotyping

All mice were genotyped using standard Polymerase Chain Reaction (PCR) of DNA extracted from ear clippings. DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen). The following primers were used to amplify DNA for determining genotype: human SOD1 transgene—fwd 5’CAT CAG CCC TAA TCC ATC TGA 3’ and rev 5’TCT TAG AAA CCG CGA CTA ACA ATC 3’; mouse endogenous SOD1—fwd 5’ GCA ATC CCA ATC ACT CCA CAG 3’ and rev 5’ GTC CAT GAG AAA CAA GAT GAC 3’; mouse endogenous Sarm1—fwd 5’ ACG CCT GTG TTA CCT TAC GA 3’ and rev 5’ OCT GGG GCC TCA TCT CTT 3’; and Sarm1 null cassette—fwd 5’ CAG GTA GGA GCA GCA TCA AGC GTA TGC 3’ and rev 5’ CCT GTC CGC TCC CCA TGA TGA ACT 3’ (Integrated DNA Technologies). Real-time quantitative PCR was used to estimate human SOD1 transgene copy number. Copy number estimation was calculated based on the difference between the threshold cycles of the hSOD1 transgene compared to an endogenous reference gene, ApoB. Mice with an estimated copy number two standard deviations outside of the average copy number for our colony were removed from the experiment.

Behavioral testing

Mice were tested weekly with an accelerating rotarod paradigm starting at p50 on a five-station rotarod for mice (Med Associates Inc.). At p50, mice were trained on the rotarod with 30 s at a constant speed of 4 rpm and 30 s at an accelerating rate starting at 4 rpm 1 day prior to the initial rotarod trial. The mice were tested for 3 non-consecutive trials with the rotarod accelerating from 4 rpm to 40 rpm for a maximum trial of 300 s. Symptomatic mice that were unable to perform on the rotarod were scored with a 0. Forelimb and all-limb grip strength was measured weekly using a digital force gauge (Mark-10, USA). Each mouse was tested five consecutive times with the highest measurement recorded in newtons (N).
MUNE
MUNE recordings were carried out as described previously (27,42). Briefly, mice were anesthetized through inhalation of isofluorane, maintained throughout the procedure via a nose cone. A single hind limb was shaved, wiped with alcohol and restrained on a Styrofoam board using adhesive tape. A recording ring electrode (CareFusion) was coated with electrode gel (SignaGel) and placed over the gastrocnemius muscle, a reference electrode over the tendon and a grounding surface electrode (CareFusion) on the tail. Disposable monopolar 28G needle electrodes were used for stimulation. The stimulating cathode was placed 5 mm proximal to the recording ring electrode, with the anode placed subcutaneously at the midline over the sacrum.

All electrophysiological recordings were made using a portable electrodiagnostic system (Cardinal Synergy). For MUNE and motor conduction studies the following settings were used: low-pass filter, 30 Hz; high-pass filter, 10 kHz; and Squarewave pulses of 0.1-ms duration. Supramaximal responses were gradually generated (typically <10 mA). The distance between distal and proximal stimulation sites was recorded. The distal latency, distal and proximal CMAP amplitudes, distal and proximal CMAP durations (measured from onset of initial negative deflection to initial return to baseline), and conduction velocity were determined for each nerve studied.

The low-pass filter was set at 20 Hz, and the high-pass filter was set at 10 kHz. Data were acquired with a sensitivity of 100 μV per division and sweep speed of 1 ms per division. Using a repetition rate of 1 per second, stimulus intensity was increased and a single motor unit response was produced. Stimulation was further increased, and quantal increases in the response were recorded. Individual motor unit amplitude of was calculated as the mean of five quantal increases. MUNE was calculated from the CMAP maximal amplitude divided by the mean amplitude of surface-detected motor unit action potential. After recording animals were euthanized by inhalation of isofluorane.

NMJ histology
Mice were euthanized via isofluorane inhalation and transcardially perfused for 2 min with Phosphate-buffered saline (PBS), followed by 5 min with 4% paraformaldehyde. The gastrocnemius muscles were dissected and fixed overnight in 1.5% paraformaldehyde and then transferred to a 25% sucrose solution overnight (4°C). After sinking, the muscles were embedded in Optimal Cutting Temperature (OCT) compound and 35 μm sections collected on a cryostat (Leica), frozen on slides and stored at −80°C. To stain for NMJs, slides were thawed completely and allowed to dry before being washed with PBS, followed by PBS with 0.4% triton-X100. The muscle sections were blocked with 10% donkey serum (EMD Millipore) in 0.4% triton-X100 PBS and then incubated overnight with a 1:5 dilution of rabbit anti-synaptophysin (Invitrogen) and a 1:1000 dilution of rabbit anti-neuronal class III beta-tubulin (Covance) primary antibodies in blocking solution. The sections were washed with PBS and then incubated overnight with 1:500 donkey anti-rabbit secondary antibody conjugated with alexa-488 (Life Technologies) and 1:500 alpha-bungarotoxin conjugated with 555 nm fluorophore (Thermo Fisher Scientific, USA) diluted in PBS. The sections were washed with PBS and coverslips were mounted with Shandon Immunomount (Fisher Scientific). NMJs were imaged on a Nikon Eclipse Ti and scored for innervation status by two investigators blinded to genotype.

Sciatic nerve axotomy
Assessment of Wallerian degeneration by lesioning of the sciatic nerve was carried out as described previously (6). Briefly, mice were anesthetized by inhalation of isofluorane, the skin was shaved and cleaned with ethanol and povidone-iodine. A 5 mm incision was made to the skin and the sciatic nerve was exposed. The sciatic nerve was grasped with fine forceps, and a 1-2 mm portion of nerve was removed, ensuring that the distal portion of nerve was lesioned completely. The incision was sutured, the mouse was treated with appropriate analgesia and returned to the home cage to recover. Mice were maintained for 14 days post-axotomy, subsequently euthanized, and the sciatic nerve was processed for semi-thin sectioning. The contralateral, intact sciatic nerve was also dissected from each animal as an internal, uninjured control.

Nerve semi-thin sectioning and toluidine blue histology
Sciatic nerves and L5 ventral nerve roots were dissected from 4% paraformaldehyde perfusion fixed mice. Following dissection nerves were immersion fixed overnight at 4°C in 2.5% gluteraldehyde in 0.1 M cacodylate buffer (pH 7.2). The following day nerves were washed in cacodylate buffer and subsequently post-fixed in 1% osmium tetroxide at room temperature for 1 hr. Following washing with dH2O, nerves were dehydrated through a graded ethanol series of 0–100% in 20% increments, followed by two changes of 100% ethanol. Nerves underwent resin infiltration through two changes of 100% propylene oxide followed by overnight incubation in a solution of 50% SPI-Pon 812 resin in propylene oxide. Samples were then rinsed with SPI-Pon 812 resin and polymerized in SPI-Pon 812 at 68°C in flat embedding molds. Semi-thin sections (0.6 μm) were collected using an ultramicrotome (Reichert-Jung UltraCut E) fitted with a diamond knife (Ultra 45°, DiATOME), mounted onto glass slides and stained with 1% toluidine blue. Images were captured using a 63× lens on a Nikon Ti-E inverted widefield microscope and stitched using Velocity software (32). Diameters of regularly shaped healthy axons were measured using ImageJ (National Institutes of Health). Images were thresholded and particles of circularity 0.5–1 and minimum diameter 0.5 μm were analyzed. Incorrectly identified objects were manually removed from the data set. Minimum diameter was used for statistical analysis. For total axons counts, healthy, irregularly shaped axons not detected by particle analysis were manually added to the data set.

Experimental design and statistical analysis
Experimental data were conducted by researchers blinded to the genotype of animals. All statistical analyses were conducted, and graphs were plotted using Graphpad Prism (GraphPad Software, Inc.). Unless stated otherwise, all charts show mean ± SEM. Statistical test used are described in the relevant results or figure legends. Tests used are unpaired t test, one-way ANOVA and two-way ANOVA with Bonferroni post-hoc testing. P-values < 0.05 were considered significant for all statistical analyses used.

Supplementary Material
Supplementary Material is available at HMG online.

Acknowledgements
The authors thank the University of Massachusetts Medical School Electron Microscopy core facility for assistance with
preparation of samples, and Jodi Raymo from University of Massachusetts Medical School Animal Medicine for excellent technical assistance.

Conflict of Interest statement. M.F. is a consultant and stockholder of Proneurotech, Inc.

Funding

ALS Therapy Alliance (to M.F. and R.H.B.); Howard Hughes Medical Institute (to M.F.); Michael J Fox Foundation Target Validation Grant (to M.F. and R.H.B.), National Institute of Neurological Disorders and Stroke (R01 NS088689 to R.H.B and R01 NS059991 to M.F.).

References

1. Salvadores, N., Sanhueza, M., Manque, P. and Court, F.A. (2017) Axonal degeneration during aging and its functional role in neurodegenerative disorders. Front. Neurosci., 11, 451.
2. Waller, A. (1850) Experiments on the section of the glosso-pharyngeal and hypoglossal nerves of the frog, and observations of the alterations produced thereby in the structure of their primitive fibres. Philos. Trans. R. Soc. Lond., 140, 423–429.
3. Lunn, E.R., Perry, V.H., Brown, M.C., Rosen, H. and Gordon, S. (1989) Absence of Wallerian degeneration does not hinder regeneration in peripheral nerve. Eur. J. Neurosci., 1, 27–33.
4. Mack, T.G., Reiner, M., Beirowski, B., Mi, W., Emanuelli, M., Wagner, D., Thomson, D., Gillingwater, T., Court, F., Conforti, L. et al. (2001) Wallerian degeneration of injured axons and synapses is delayed by a Ub4h/Nmnat chimeric gene. Nat. Neurosci., 4, 1199–1206.
5. Coleman, M.P. and Freeman, M.R. (2010) Wallerian degeneration, wld(s), and nmnat. Annu. Rev. Neurosci., 33, 245–267.
6. Osterloh, J.M., Yang, J., Rooney, T.M., Fox, A.N., Adalbert, R., Powell, E.H., Sheehan, A.E., Avery, M.A., Hackett, R., Logan, M.A. et al. (2012) dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. Science, 337, 481–484.
7. Gerds, J., Summers, D.W., Sasaki, Y., DiAntonio, A., and Milbrandt, J. (2013) Sarm1-mediated axon degeneration requires both SAM and TIR interactions. J. Neurosci. Off. J. Soc. Neurosci., 33, 13569–13580.
8. Babetto, E., Beirowski, B., Russler, E.V., Milbrandt, J. and DiAntonio, A. (2013) The Phr1 ubiquitin ligase promotes injury-induced axon self-destruction. Cell Rep., 3, 1422–1429.
9. Neukomm, L.J., Burdett, T.C., Gonzalez, M.A., Züchner, S. and Freeman, M.R. (2014) Rapid in vivo forward genetic approach for identifying axon death genes in Drosophila. Proc. Natl. Acad. Sci. U.S.A., 111, 9965–9970.
10. Xiong, X., Hao, Y., Sun, K., Li, J., Li, X., Mishra, B., Soppina, P., Wu, C., Hume, R.I. and Collins, C.A. (2012) The Highwire ubiquitin ligase promotes axonal degeneration by tuning levels of Nmnat protein. PLoS Biol., 10, e1001440.
11. Neukomm, L.J., Burdett, T.C., Seeds, A.M., Hamps, S., Coutinho-Budd, J.C., Farley, J.E., Wong, J., Karadeniz, Y.B., Osterloh, J.M., Sheehan, A.E. et al. (2017) Axon death pathways converge on axunead to promote functional and structural axon disassembly. Neuron, 95, 78–91.e5.
12. Wang, M.S., Fang, G., Culver, D.G., Davis, A.A., Rich, M.M. and Glass, J.D. (2001) The WldS protein protects against axonal degeneration: a model of gene therapy for peripheral neuropathy. Ann. Neurol., 50, 773–779.
13. Wang, M.S., Davis, A.A., Culver, D.G. and Glass, J.D. (2002) WldS mice are resistant to paclitaxel (taxol) neuropathy. Ann. Neurol., 52, 442–447.
14. Mi, W., Beirowski, B., Gillingwater, T., Adalbert, R., Wagner, D., Grumme, D., Osaka, H., Conforti, L., Arnhold, S., Addicks, K. et al. (2005) The slow Wallerian degeneration gene, WldS, inhibits axonal spheroid pathology in gracile axonal dystrophy mice. Brain, 128, 405–416.
15. Beirowski, B., Babetto, E., Coleman, M.P. and Martin, K.R. (2008) The WldS gene delays axonal but not somatic degeneration in a rat glaucoma model. Eur. J. Neurosci., 28, 1166–1179.
16. Lorber, B., Tassoni, A., Bull, N.D., Moschos, M.M. and Martin, K.R. (2012) Retinal ganglion cell survival and axon regeneration in WldS transgenic rats after optic nerve crush and lens injury. BMC Neurosci., 13, 56.
17. Hashani, D.M. and O’Malley, K.L. (2006) Wld(S) mice are protected against the Parkinsonian mimetic MPTP. Exp. Neurol., 202, 93–99.
18. Sajadi, A., Schneider, B.L. and Aebischer, P. (2004) WldS-mediated protection of dopaminergic fibers in an animal model of Parkinson disease. Curr. Biol. CB, 14, 326–330.
19. Ferri, A., Sanes, J.R., Coleman, M.P., Cunningham, J.M. and Kato, A.C. (2003) Inhibiting axon degeneration and synapse loss attenuates apoptosis and disease progression in a mouse model of motoneuron disease. Curr. Biol. CB, 13, 669–673.
20. Fischer, L.R., Culver, D.G., Davis, A.A., Tennant, P., Wang, M., Coleman, M., Assess, S., Adalbert, R., Alexander, G.M. and Glass, J.D. (2005) The WldS gene modestly prolongs survival in the SOD1G93A fALS mouse. Neurobiol. Dis., 19, 293–300.
21. Vande Velde, C., Garcia, M.L., Yin, X., Trapp, B.D. and Cleveland, D.W. (2004) The neuroprotective factor WldS does not attenuate mutant SOD1-mediated motor neuron disease. Neuromolecular Med., 5, 193–203.
22. Gilley, J., Ribchester, R.R. and Coleman, M.P. (2017) Sarm1 deletion, but not WldS, confers lifelong rescue in a mouse model of severe axonopathy. Cell Rep., 21, 10–16.
23. Peters, O.M., Ghassemi, M. and Brown, R.H. (2015) Emerging mechanisms of molecular pathology in ALS. J. Clin. Invest., 125, 1677–1679.
24. Fogh, I., Ratti, A., Gellera, C., Lin, K., Tiloca, C., Moskvina, V., Corrado, L., Soraru, G., Cereda, C., Corti, S. et al. (2014) A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. Hum. Mol. Genet., 23, 2220–2231.
25. Gurney, M.E., Pu, H., Chiu, A.Y., Dal Canto, M.C., Polchow, C.Y., Alexander, D.D., Cariello, J., Hentati, A., Kwon, Y.W. and Deng, H.X. (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Ann. Neurol., 36, 78–91.e5.
26. Combas, A.J., Fawcett, P.R., Campbell, M.J. and Sica, R.E. (1997) Electrophysiological estimation of the number of motor units within a human muscle. J. Neurol. Neurosurg. Psychiatry, 60, 128–135.
27. Shefner, J.M., Cudkowicz, M.E. and Brown, R.H. (2002) Comparison of incremental with multipoint MUNE methods in transgenic ALS mice. Muscle Nerve, 25, 39–42.
28. Shefner, J.M., Watson, M.L., Simionescu, L., Caress, J.B., Burns, T.M., Maragakis, N.J., Benatar, M., David, W.S., Sharma, K.R. and Rutkove, S.B. (2011) Multipoint incremental motor
37. Rogers, R.S., Tungtur, S., Tanaka, T., Nadeau, L.L., Badawi, Y., Wang, H., Ni, H.-M., Ding, W.-X. and Nishimune, H. (2017) Impaired mitophagy plays a role in denervation of neuromuscular junctions in ALS mice. *Front. Neurosci.*, 11.

38. Song, W., Song, Y., Kincaid, B., Bossy, B. and Bossy-Wetzel, E. (2013) Mutant SOD1G93A triggers mitochondrial fragmentation in spinal cord motor neurons: neuroprotection by SIRT3 and PGC-1α. *Neurobiol. Dis.*, 51, 72–81.

39. Harlan, B.A., Pehar, M., Sharma, D.R., Beeson, G., Beeson, C.C. and Vargas, M.R. (2016) Enhancing NAD+ salvage pathway reverts the toxicity of primary astrocytes expressing amyotrophic lateral sclerosis-linked mutant superoxide dismutase 1 (SOD1). *J. Biol. Chem.*, 291, 10836–10846.

40. Clark, J.A., Southam, K.A., Blizzard, C.A., King, A.E. and Dickson, T.C. (2016) Axonal degeneration, distal collateral branching and neuromuscular junction architecture alterations occur prior to symptom onset in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. *J. Chem. Neuroanat.*, 76, 35–47.

41. Henninger, N., Bouley, J., Sikoglu, E.M., An, J., Moore, C.M., King, J.A., Bowser, R., Freeman, M.R. and Brown, R.H. (2016) Attenuated traumatic axonal injury and improved functional outcome after traumatic brain injury in mice lacking Sarm1. *Brain J. Neurol.*, 139, 1094–1105.

42. Shefner, J.M., Cudkowicz, M. and Brown, R.H. (2006) Motor unit number estimation predicts disease onset and survival in a transgenic mouse model of amyotrophic lateral sclerosis. *Muscle Nerve*, 34, 603–607.

43. Sharp, P.S., Dick, J.R. and Greensmith, L. (2005) The effect of peripheral nerve injury on disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. *Neuroscience*, 130, 897–910.

44. Geisler, S., Doan, R.A., Strickland, A., Huang, X., Milbrandt, J. and DiAntonio, A., (2016) Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice. *Brain.*, 139, 3092–3108.